Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031

The Cardiac Biomarkers Market was valued at $5.15 billion in 2023. This market is expected to reach $10.08 billion by 2031 from an estimated $5.57 billion in 2024, at a CAGR of 8.8% during the forecast period of 2024-2031.

Cardiac Biomarkers Market Size & Forecast

The growth of the cardiac biomarkers market is driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, technological advancements in cardiac biomarkers, increasing healthcare expenditure, and increasing cardiovascular disease awareness programs. Furthermore, the introduction of novel biomarkers tests and integration of biomarkers in point-of-care testing are expected to generate growth opportunities for the stakeholders in this market.

Key Findings

• By Type: The Troponin Segment Dominated the Cardiac Biomarkers Market in 2024.
• By Application: The Myocardial Infarction Segment Dominated the Cardiac Biomarkers Market in 2024.
• By End User: The Laboratory Testing Dominated the Cardiac Biomarkers Market in 2024.

Cardiac biomarkers Market Growth Drivers

Increasing Prevalence of Cardiovascular Diseases and Rising Geriatric Population

The rising prevalence of cardiovascular diseases due to changing lifestyle factors such as poor diet intake, growing consumption of alcohol are the major driving factors of increasing cardiovascular disease cases.  The rising cases of heart attack due to changing lifestyles, environmental factors, and growing geriatric population are contributing to the growth of the cardiac biomarker market. According to the World Health Organization (WHO), about 32% of global deaths, out of these, 85% were due to heart attack and stroke in 2019. Around 805,000 individuals in the U.S. are suffering from heart attack. Out of these 605,000 are a first heart attack (source: Centers for Disease Control and Prevention (CDC)).  According to Heart Failure society of America stats 2024: Heart Failure Epidemiology and Outcomes Statistics, around 6.7 million Americans over the age of 20 living with heart failure, and this figure is expected to rise 8.7 million by 2030. These rising cases of cardiovascular diseases are expected to drive the demand for cardiac biomarkers in the market.

Additionally, the rising geriatric population is one of the major contributing factors to the growth of cardiac biomarkers market. According to the World Health Organization (WHO) the number and proportion of people aged 60 years and older is increasing. It is expected that it will increase to 1.4 billion by 2030 and 2.1 billion by 2050. There is a high incidence of heart related diseases shown in people due to rising age. This factor also creates a demand for cardiac biomarkers as preventive care diagnostic solution in the aged population. These factors are expected to increase the adoption of cardiac biomarkers and eventually drive the growth of the market.

Increasing Cardiovascular Disease Awareness Programs

The increasing awareness about cardiovascular diseases through different awareness programs is one of the major driving factors for the growth of the cardiac biomarkers market. The heart disease and stroke are majorly responsible factor for 1 in 4 deaths in the United States each year. In addition, 120 million people have high blood pressure, a major risk factor for heart disease and stroke and an increasingly common cause of pregnancy complications. To spread awareness among the population regarding cardiovascular diseases various organizations and institutes are running awareness campaigns and programs. The Heart Truth is a national education program that raises awareness about heart disease and its risk factors. This program is brought by National Heart, Lung, and Blood Institute (NHLBI) (U.S.). The aim is to spread awareness among the population about heart diseases and make positive changes in public health. It is expected that rising awareness programs are contributing to the high adoption of cardiac biomarkers as a preventive care solution in the market. These factors are expected to drive the growth of the cardiac biomarkers market.

Cardiac biomarkers Market Growth Trends

Trends Focus on Multi-Analyte Panels

Multianalyte panels combine multiple biomarkers which reflect various aspects of cardiovascular health. By analyzing multiple biomarkers simultaneously, these panels provide a more accurate and comprehensive assessment of cardiac conditions in patients. Additionally, these panels help healthcare providers to assess a patient's risk more effectively by evaluating several biomarkers which reflect different physiological processes, such as oxidative stress, inflammation, and myocardial injury. These panels also allow for more precise stratification of patients based on their risk of developing serious cardiac events. Moreover, early disease detection is crucial for preventing the progression of diseases like coronary artery disease (CAD) or heart failure which enables earlier and more effective interventions. These panels can also help in monitoring the progression of cardiovascular diseases over time by tracking multiple biomarkers related to disease severity and response to treatment. Healthcare providers can adjust treatment plans based on how the patient is evolving and ensuring optimal care. Thes factors are expected to drive the growth of the market and lead to higher adoption of cardiac biomarkers among the patients and healthcare providers.

Cardiac biomarkers Market Opportunities

Integration of Biomarkers in Point-of-Care Testing

Integration of biomarkers in point-of-care testing can create a growth of opportunities for cardiac biomarkers market. One of the primary advantages of POC testing is the ability to provide real-time results which allow healthcare providers to make immediate clinical decisions. For different cardiac conditions like heart attack rapid biomarker testing at the point of care can significantly reduce time of diagnosis, enables faster interventions, and results in better patient outcomes. It can be particularly valuable in emergency settings where timely diagnosis is critical.  This capability of point-of-care testing can make biomarkers a routine part of emergency care and drive demand for such tests.

Moreover, convenience offered by these solutions can increase the adoption of cardiac biomarkers in the market. POC testing can be performed in various settings, including emergency rooms, doctor's offices, ambulances, and even at home. Patients can receive quick results without needing to wait for lab-based testing or travel to medical centers. This convenience helps in improving patient satisfaction and encourages greater utilization of cardiac biomarkers, expanding their market reach. These factors are expected to create growth opportunities for the cardiac biomarkers market.

Cardiac Biomarkers Market Analysis: Top Market Opportunity

By Type: In 2024, Troponin Segment Dominated the Cardiac Biomarkers Market

Based on type, the cardiac biomarkers market is segmented into Troponin, Creatine Kinase MB (CK-MB), Myoglobin, B-Type Natriuretic Peptide (BNP), N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Types. In 2024, the troponin segment accounted for the largest share of 51.7 of the cardiac biomarkers market. The large share of this segment is attributed to the high sensitivity and specificity in detecting Myocardial infarction, key features of troponin, new product launches, major players offering troponin testing products, and advancements in high sensitivity troponin tests.

However, the B-type natriuretic peptide (BNP) segment is expected to grow at the highest CAGR of during the forecast period of 2024 to 2031. Rising heart failure cases, collaboration with pharmaceutical companies, clinical guidelines are highly recommended BNP for diagnosis and monitoring, and advancements in BNP assays. These factors contribute to the fastest growth of the segment. For instance, in January 2022, Arbor Assays, Inc. (U.S.) has launched a new human B-Type Natriuretic Peptide (BNP) ELISA kits to detect BNP and proBNP for heart failure and cardiac dysfunction.

By End User: In 2024, Laboratory Testing Segment Dominated the Cardiac Biomarkers Market

Based on end user, the global cardiac biomarkers market is segmented into laboratory testing and point-of care testing. In 2024, the laboratory testing segment accounted for the largest share of 59.7% of the global cardiac biomarkers market. The large market share of this segment is attributed to the rising number of diagnostics laboratories, increasing awareness about early disease diagnosis, availability of skilled professionals, and increasing investments in developing healthcare infrastructure.

Geographic Analysis

North America Dominated the Cardiac biomarkers Market in 2024

In 2024, North America accounted for the largest share of 39.5% of the global cardiac biomarkers market. The region’s large share of the cardiac biomarkers market is primarily attributed to increasing prevalence of cardiovascular diseases coupled with rising geriatric population, increasing sedentary lifestyle, rising consumption of alcohol & caffeine, well-established healthcare system, high awareness of cardiovascular diseases, high healthcare expenditure, presence of major key players in this region. As the number of cases of cardiovascular disease rises, consequently increases the demand for diagnostic tools such as cardiac biomarkers in the U.S.

However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. This market’s growth is attributed to increasing burden of patients with CVDs, rising urbanization, changing lifestyle, rising healthcare expenditure, developing healthcare infrastructure, increasing geriatric population, rising focus of the key players to expand in emerging countries like China & India. According to the Journal of the American College of Cardiology (JACC), CVD mortality rates among countries in High-income Asia Pacific ranges from 72.7 to 252.6 per 100,000 in 2022. Out of the twenty-one regions, high-income Asia Pacific was ranked 21st in 2022 for age-standardized CVD mortality. This shows a high burden of deaths in the region due to cardiovascular diseases.

Cardiac Biomarkers Market: Key Companies

The report includes a competitive landscape based on an extensive assessment of the product offerings, geographic presence, and key strategic developments of leading market players (2021–2024). The key players operating in the cardiac biomarkers market are Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), BioMérieux SA (France), Danaher Corporation (U.S.), Creative Diagnostics (U.S.), Life Diagnostics, Inc. (U.S.), Randox Laboratories Ltd. (U.K), Becton, Dickinson and Company (U.S.), and QuidelOrtho Corporation (U.S.).

Cardiac Biomarkers Market Overview: Latest Developments from Key Industry Players

• In October 2024, Siemens Healthineers received FDA approval of a new progressive claim for Atellica IM high-sensitivity troponin I (TnIH) test for predicting Heart Attack.
• In June 2024, Siemens Healthineers introduced the NT-proBNPII (PBNPII) assay to its cardiac portfolio on the Atellica Solution for diagnosing heart failure.
• In May 2024, Beckman Coulter, Inc. (U.S.) received FDA approval for its Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay for the examination of heart failure in less than 11 minutes on Beckman Coulter DxI 9000 Immunoassay Analyzer.
• In April 2024, Roche Diagnostics India launched point-of-care (PoC) NT-proBNP test for screening of diabetes in patients at a risk of cardiovascular diseases such as heart failure.
• In April 2023, Bio-Rad launched Cardiac Advance quality controls for high sensitivity troponin testing.
• In December 2022, QuidelOrtho Corporation received approval from Health Canada for Quidel TriageTrue High-Sensitivity Troponin I Test for commercial use in Canada to aid in the diagnosis of myocardial infarction.
• In May 2022, Quidel Corporation and Ortho Clinical Diagnostics Holdings plc is merged to form QuidelOrtho Corporation to provide in vitro diagnostics solutions.
• In July 2021, Beckman Coulter, Inc. (U.S.) signed an agreement with QuidelOrtho Corporation (U.S.) to obtain Beckman Coulter all manufacturing, distribution, and sales rights for BNP assay. This agreement aims to improve Beckman Coulter’s capabilities in cardiovascular diagnostics.

Cardiac Biomarkers Market Research Summary

Key questions answered in the cardiac biomarkers market report: